Sanofi has announced that a large-scale public programme to immunise 500,000 individuals with Dengvaxia dengue vaccine has been launched in the Americas.

The dengue prevention programme will start in Paraná state, Brazil, which reported 55,000 cases in the last year.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Paraná health secretary Michele Caputo Neto said: “For the public immunisation programme being launched today, we have used our extensive dengue surveillance data to ensure that we are targeting people at highest risk of disease.

"We will vaccinate all individuals 15 to 27 years of age in 28 municipalities, and nine to 44 years of age in the two municipalities with the top dengue burden in our state over the next three weeks.

" … Successful implementation of Dengvaxia in a large-scale public programme in Paraná will serve as a benchmark for dengue prevention efforts elsewhere in the country and in the world."

“Paraná has a good track record in vaccination coverage in general, and successful implementation of this dengue immunisation strategy could result in a 74% reduction in disease burden in these highly impacted municipalities within five years, according to a dengue vaccine impact study published in the Brazilian Journal of Health Economics.”

See Also:

The safety and efficacy of Sanofi’s Dengvaxia dengue vaccine has been independently endorsed by the World Health Organisation (WHO).

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

During Phases II and III of the clinical development of the vaccine, more than 40,000 people participated in both studies conducted in 15 countries worldwide, including Brazil.

Sanofi Pasteur Guillaume Leroy said: “Introduction of the dengue vaccine first in endemic countries like Brazil has always been Sanofi Pasteur’s priority because this is where the vaccine can have the greatest impact on disease burden globally.

“Furthermore, successful implementation of Dengvaxia in a large-scale public programme in Paraná will serve as a benchmark for dengue prevention efforts elsewhere in the country and in the world.”